UPDATE: Jefferies Raises PT on Endo Health Following DeSilva Public Appearance
In a report published Friday, Jefferies analyst Corey Davis reiterated a Buy rating on Endo Health Solutions (NASDAQ: ENDP), and raised the price target from $37.00 to $45.00.
In the report, Jefferies noted, “ENDP CEO Rajiv DeSilva made his 1st public appearance at our conference today. Despite <4 months as CEO, Mr. DeSilva showed an impressive grasp of the business and inspired confidence in his new model: 1) M&A will be a clear focus, 2) the decentralized ‘lean pharma' model is gaining credibility, & 3) a worst-case scenario now yields $3.58 EPS as a trough in 2014 before growth after '15. Raise target to $45.”
Endo Health Solutions closed on Thursday at $35.96.
Latest Ratings for ENDP
|Jan 2016||Barclays||Initiates Coverage on||Equal-weight|
|Nov 2015||Mizuho Securities||Downgrades||Buy||Neutral|
|Nov 2015||Standpoint Research||Upgrades||Hold||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.